Company Announcements
Date
Title
25 March
QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers
24 March
Non-executive Director resignation
28 February
February 2025 Shareholder Update
17 February
QBiotics data presented at Society of Surgical Oncology Advanced Cancer Therapies 2025 Annual Meeting
7 February
31 December 2024 Interim Financial Report
5 February
STELFONTA® label extended in Great Britain
23 January
QBiotics strengthens medical leadership with appointment of CMO and world leading oncologist consultant
26 November
QBiotics receives $7.38m R&D tax incentive refund
22 November
2024 Annual General Meeting - CEO Presentation and Results of the Meeting
19 November
Bell Potter Healthcare Conference presentation
19 November
QBiotics Phase IIa Soft Tissue Sarcoma trial extended, following positive data presented at CTOS
19 November
QBiotics board changes
7 November
Mark Fladrich appointed Chair of QBiotics
5 November
Vale Dr Susan Foden, Non-executive Chair
23 October
QBiotics leadership transition
23 October
2024 Annual General Meeting
17 September
Preliminary data from QBiotics’ Phase IIa clinical trial in Soft Tissue Sarcoma presented at ESMO Congress 2024
12 September
QBiotics appoints world class Clinical Advisory Board
26 August
2024 Annual Report
23 August
August 2024 Shareholder Update
5 August
QBiotics welcomes Stephen Doyle as Chief Executive Officer
11 June
QBiotics Phase IIa clinical trial in Soft Tissue Sarcoma completion of patient recruitment
6 June
QBiotics receives $8.63m R&D tax incentive refund
31 May
May 2024 Shareholder Update
28 May
QBiotics to present at the 10th Annual Sachs Oncology Innovation Forum 2024 and BIO International Convention 2024
20 May
Board appointments at QBiotics Group
3 May
Tigilanol tiglate preclinical data published in Journal for ImmunoTherapy of Cancer
26 February
31 December 2023 Interim Financial Report
21 February
February 2024 Shareholder Update
16 February
QBiotics drug tigilanol tiglate awarded Orphan Drug Designation for patients with soft tissue sarcoma
23 November
Annual General Meeting Shareholder Presentation 2023
16 November
Board and Executive changes at QBiotics Group
16 October
New STELFONTA® data presented at the 2023 Veterinary Cancer Society Annual Conference
12 October
QBiotics to present advances from its oncology and wound healing programmes at key conferences in October and November
1 September
2023 Annual Report
18 August
August 2023 Shareholder Update
16 August
QBiotics’ tigilanol tiglate meets Primary Endpoints in its Phase I/IIa head and neck cancer dose escalation trial
9 June
First patient treated in QBiotics' Phase II clinical trial in patients with soft tissue sarcoma
8 June
BIO International Convention presentation
2 June
Sachs 9th Annual Immuno-Oncology Innovation Forum presentation
31 May
QBiotics to present at Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention
30 May
Changes to the Board of Directors
29 May
May 2023 Shareholder Update
24 April
QBiotics opens Phase II clinical trial to investigate the preliminary efficacy of Tigilanol Tiglate in soft tissue sarcoma
29 March
First patient treated in QBiotics’ Phase II Clinical Trial treating head and neck cancer with tigilanol tiglate
7 March
31 December 2022 Interim Financial Report
14 February
QBiotics announces amended human clinical strategy for tigilanol tiglate and Non-executive Director resignation
22 December
QBiotics Poster Presentation at SITC 2022
11 December
Update of QBiotics Group human oncology clinical trials
8 December
QBiotics appoints new Chair and Deputy Chair
2 December
Resignation of non-executive chair
21 November
Annual General Meeting CEO Presentation 2022
13 September
30 June 2022 Annual Report
25 July
FDA approves IND to initiate soft tissue sarcoma (STS) trial
22 March
COVID-19 impact update
14 March
31 December 2021 Interim Financial Report
2 March
Phase I/II trial (QBC46-H03) completes recruitment
15 December
STELFONTA® launches in Australia
7 July
APVMA approves registration of STELFONTA
28 June
QBiotics concludes successful $85 million capital raise
3 June
First patient dosed in QBiotics and MSD clinical trial collaboration for unresectable melanoma
25 May
Prospectus – Offer opens and Application Forms now available
17 May
QBiotics lodges Prospectus in preparation for share offer to Existing Shareholders
20 April
QBiotics raises AU$22.55 million from existing Sophisticated Investors
9 April
Hamish Corlett joins the Board of QBiotics
1 April
QBiotics announces plan to increase capital raise to up to AU$85 million
16 March
Cornerstone Investor Joins QBiotics
16 March
QBiotics announces plan to raise up to AU$75 million
16 March
QBiotics welcomes TDM Growth Partners as cornerstone investor
24 February
QBiotics’ first USA shipment of STELFONTA®
1 February
Nicholas Moore joins the Board of QBiotics
17 November
FDA approves registration of STELFONTA®
21 September
STELFONTA® USA Marketing Authorisation Progress
13 August
QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
22 July
QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer
17 June
Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours
27 April
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
February
QBiotics raises AU$17.76 million from Sophisticated Investors
20 January
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®
10 December
The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal
3 December
QBiotics announces first patient dosed in its Phase I/II clinical trial of tigilanol tiglate for head and neck cancer
November
STELFONTA Progress with European Medicines Authority
14 October
Dr Susan Foden joined the Board of QBiotics
October
Scientific Presentations: Veterinary Cancer Society, Houston, USA
September
Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses
April
International Publication - Tigilanol Tiglate Canine Dose Characterisation Study